RCAG
ACAD icon

Rehmann Capital Advisory Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Rehmann Capital Advisory Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-12
Closed -$320 – 1690
2019
Q2 		$320 Sell
12
-68
-85% -$1.74K ﹤0.01% 2011
2019
Q1 		$2.15K Sell
80
-405
-84% -$9.46K ﹤0.01% 1746
2018
Q4 		$7.84K Buy
485
+417
+613% +$8.1K ﹤0.01% 1129
2018
Q3 		$1.41K Sell
68
-238
-78% -$3.75K ﹤0.01% 1899
2018
Q2 		$4.67K Sell
306
-323
-51% -$5.76K ﹤0.01% 1559
2018
Q1 		$14K Buy
+629
New +$17.4K ﹤0.01% 1186

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $408M AUM 318.81% 1-Year Est. Return